Characteristics of patients included in this study
Patients, no. . | 401 . |
|---|---|
| Median age, y (range) | 60.3 (16.8-81.9) |
| Sex, no. M/F | 202/199 |
| FAB subtype | |
| M0, no. (%) | 3 (0.7) |
| M1, no. (%) | 96 (23.9) |
| M2, no. (%) | 133 (33.2) |
| M4, no. (%) | 93 (23.2) |
| M5a, no. (%) | 14 (3.5) |
| M5b, no. (%) | 29 (7.2) |
| M6, no. (%) | 25 (6.2) |
| Not further specified, no. (%) | 8 (2.0) |
| Etiology, no. (%) | |
| Primary AML | 373 (93.0) |
| s-AML following MDS | 20 (5.0) |
| t-AML | 8 (2.0) |
Patients, no. . | 401 . |
|---|---|
| Median age, y (range) | 60.3 (16.8-81.9) |
| Sex, no. M/F | 202/199 |
| FAB subtype | |
| M0, no. (%) | 3 (0.7) |
| M1, no. (%) | 96 (23.9) |
| M2, no. (%) | 133 (33.2) |
| M4, no. (%) | 93 (23.2) |
| M5a, no. (%) | 14 (3.5) |
| M5b, no. (%) | 29 (7.2) |
| M6, no. (%) | 25 (6.2) |
| Not further specified, no. (%) | 8 (2.0) |
| Etiology, no. (%) | |
| Primary AML | 373 (93.0) |
| s-AML following MDS | 20 (5.0) |
| t-AML | 8 (2.0) |
s-AML indicates secondary AML after myelodysplasia; MDS, myelodysplastic syndrome; and t-AML, therapy-related AML.